Patents Represented by Attorney, Agent or Law Firm Ingrid A. Beattie, Esq.
  • Patent number: 6638717
    Abstract: The present invention relates to a highly efficient, high-throughput method for the identification and elimination of redundancy in a population of nucleic acid molecules using microarrays. This method involves a reiterative subtraction protocol that creates a library that becomes more biased toward unknown genes with each successive round. The removal of repetitive and previously characterized nucleic acids from the library allows the identification of low-abundance mRNA from sources of interest and enhances the rate of novel gene discovery. The present invention is also useful for the removal of contaminating nucleic acids from cloning libraries.
    Type: Grant
    Filed: May 19, 1999
    Date of Patent: October 28, 2003
    Assignee: Aventis Pharmaceuticals, Inc.
    Inventors: Steven Perrin, Kathy Call, Timothy Connolly
  • Patent number: 6521616
    Abstract: The invention provides a method of inhibiting tumor growth in a mammal, by administering to the mammal composition containing taurolidine, taurultam, or a biologically active derivative thereof. The composition is administered to directly contact a tumor cell at a dose sufficient to induce cell death by apoptosis.
    Type: Grant
    Filed: December 6, 2000
    Date of Patent: February 18, 2003
    Assignee: Rhode Island Hospital, A Lifespan Partner
    Inventors: Paul Calabresi, James Darnowski
  • Patent number: 6511807
    Abstract: The present invention provides a substantially purified carbohydrate ligand that specifically binds to a leczyme. The invention also provides methods to identify a carbohydrate ligand that specifically binds to a leczyme or a leczyme that specifically binds to a carbohydrate ligand. The invention further provides methods to identify a peptide that binds to the carbohydrate ligand binding site of a leczyme. The present invention provides methods to isolate a carbohydrate ligand or a leczyme and to identify a carbohydrate ligand or a leczyme that modifies the function of a cell and to obtain such functionally modified cells. The invention further provides methods to modify a cell to express a carbohydrate ligand by introducing an expression vector encoding a leczyme into the cell. The invention also provides methods to modulate the immune response to an antigen by administering the antigen and a carbohydrate ligand.
    Type: Grant
    Filed: December 6, 2000
    Date of Patent: January 28, 2003
    Inventor: Barry E. Rothenberg